DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Lipocine Inc. Of Upcoming Deadline

Wilmington, Delaware, UNITED STATES


WILMINGTON, Del., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:

  • Do you, or did you, own shares of Lipocine Inc. (NASDAQ:LPCN)?

  • Did you purchase your shares between June 30, 2015 and June 28, 2016, inclusive?

  • Did you lose money in your investment?

Rigrodsky & Long, P.A. reminds shareholders of Lipocine Inc. (“Lipocine” or the “Company”) (NASDAQ:LPCN) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.  A complaint was filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the common stock of Lipocine between June 30, 2015 and June 28, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects.  Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) the Company’s filing of its New Drug Application (“NDA”) for its lead product candidate, TLANDOTM (“LPCN 1021”), to the U.S. Food and Drug Administration (“FDA”) contained deficiencies; and (2) as a result, Defendants’ statements about Lipocine’s business and operations were false and misleading and/or lacked a reasonable basis.  As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than August 30, 2016.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

If you purchased shares of Lipocine during the Class Period, or purchased shares prior to the Class Period and still hold Lipocine, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to info@rl-legal.com; or at: http://rigrodskylong.com/investigations/lipocine-inc-lpcn.

Attorney advertising.  Prior results do not guarantee a similar outcome.


        

Contact Data